RE:RE:7%Hey Proph as to ABCL maybe its time for an update.
-They are on schedule to complete their GMP lab next year to advance a multi year plan to become a vertically integrated drug develpoer
-They recently expanded their partnership with Regeneron and iniciated a new program with Incyte.
-They currently have 9 molecules in clinical trials
-Insiders have been heavy buyers all year
-They have about a billion in totally liquidity against a market cap of 1.4
-Managment is fast and agile as always. When covid hit instead of shutting down and making excuses they created a 1 billion dollar payday. Contrast this with Ceapro that totally missed the marijuana opportunioty that the market was screaming at them to take in 2017.
-Everyone should have ABCL on their screen right now they have big catalysts including T cell engager platform and in house drug discovery program.
Cheers all
Hey Proph throw us one of your picks .